NEKTAR THERAPEUTICS

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines in immunotherapy. The company creates new immunomodulatory agents designed to selectively induce, amplify, attenuate, or prevent immune responses to achieve therapeutic outcomes. Nektar applies its understanding of immunology to identify and create drug candidates and advance them through preclinical and clinical development. Nektar's pipeline includes clinical-stage and preclinical-stage immunomodulatory agents targeting autoimmune diseases and cancer. For autoimmune diseases, examples include rezpegaldesleukin and NKTR-0165/0166, respectively. For cancer, an example is NKTR-255. The company invests in building and advancing its pipeline of drug candidates. Nektar's drug candidates modulate the immune system to target pathways critical in various serious diseases. In autoimmune diseases, the focus is on addressing immune system imbalances to restore self-tolerance mechanisms and achieve immune homeostasis. In oncology, the focus is on activating the immune system's natural tumor-fighting mechanisms. Many autoimmune diseases are caused by an immune system imbalance, where a failure of self-tolerance mechanisms leads to pathogenic T cells attacking healthy cells. Current systemic treatments, such as corticosteroids and anti-TNF agents, broadly suppress the immune system with severe side effects. Nektar aims to rebalance the immune system by increasing the function of regulatory T cells (Treg cells) to treat autoimmune and inflammatory disorders. Rezpegaldesleukin is a drug candidate that may address this underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases.